Skip to main content


Breast Cancer Research and Treatment

Breast Cancer Research and Treatment OnlineFirst articles

22.05.2019 | Brief Report

Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy

Metaplastic breast cancer (MetaBC) accounts for < 1% of all breast malignancies [ 1 ]. Metaplastic carcinomas represent a morphologically heterogenous group of invasive breast cancers in which a variable portion of the glandular epithelial cells …

22.05.2019 | Letter to the Editor

What is the best clinical pathological score to identify high-risk patients with lobular carcinoma of the breast who are likely to benefit from adjuvant chemotherapy?

22.05.2019 | Preclinical study

Potent inhibition of breast cancer by bis-indole-derived nuclear receptor 4A1 (NR4A1) antagonists

The 48 members of the nuclear receptor (NR) superfamily of transcription factors play essential roles in maintain cellular homeostasis and are also potential druggable targets for many diseases including cancer [ 1 , 2 ]. Pharmaceutical agents that …

22.05.2019 | Preclinical study Open Access

Breast cancer outcome prediction with tumour tissue images and machine learning

There is a growing interest around the potential of machine learning to improve the accuracy of medical diagnostics [ 1 ]. Novel machine learning techniques have not only advanced the state-of-the-art in several pattern recognition tasks [ 2 , 3 ] …

22.05.2019 | Epidemiology

Does time to adjuvant chemotherapy (TTC) affect outcomes in patients with triple-negative breast cancer?

Triple-negative breast cancers (TNBCs), characterized by lack of expression of hormone and HER2 receptors, account for ~ 15% of all breast cancer subtype diagnoses [ 1 ]. Although adjuvant chemotherapy has improved recurrence and mortality rates …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.